GLMD - Galmed Pharmaceuticals Ltd.

QQQ $ 629.16 $ 3.02 (0.48 %)

DIA $ 475.58 $ 0.66 (0.14 %)

SPY $ 681.80 $ 2.23 (0.33 %)

TLT $ 90.21 $ -0.27 (-0.3 %)

GLD $ 368.20 $ -2.01 (-0.54 %)

Previous Close

$ 1.37

Open

$ 1.34

Bid

$ 1.30 x 1,010

Ask

$ 1.38 x 50

Day's Range

$ 1.34 - $ 1.37

52 Week Range

$ 1.15 - $ 3.61

Volume

13,767

Average Volume

Market Cap

2.27M

Beta (5Y Monthly)

$ 1.13

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12 Health Care Stocks Moving In Monday's A...
10/13/2025 21:06:47

12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 12:08:21

12 Health Care Stocks Moving In Thursday's...
09/11/2025 21:06:02

Galmed Pharmaceuticals Q2 EPS $(0.63) Beat...
08/28/2025 13:36:46

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate o...

12 Health Care Stocks Moving In Thursday's...
08/28/2025 12:08:20

Galmed Board Approves Digital Asset Manage...
08/25/2025 11:37:58

why-palo-alto-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket

Why Palo Alto Shares Are Trading Higher By...
08/19/2025 12:01:09

12 Health Care Stocks Moving In Friday's P...
06/20/2025 12:09:39

Galmed Pharma Announces Discovery Of Propr...
05/27/2025 12:03:49

Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic ...

Galmed Pharmaceuticals Q1 EPS $(0.62) Beat...
05/22/2025 12:13:51

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate o...

Galmed Pharma: First Set Of Oncology Studi...
05/06/2025 11:39:03

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combinati...

crude-oil-down-2-roper-technologies-increases-2025-outlook

Crude Oil Down 2%; Roper Technologies Incr...
04/28/2025 16:38:56

dow-jumps-over-150-points-dominos-pizza-posts-upbeat-earnings

Dow Jumps Over 150 Points; Domino's Pizza ...
04/28/2025 13:56:16

Galmed Pharmaceuticals Enters Sponsored P...
04/17/2025 12:33:21

Galmed Pharmaceuticals (NASDAQ:GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to e...

Galmed Unveils Pharmacodynamic Blood Marke...
04/15/2025 12:32:45

Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights int...

Galmed Announces Part 1 Results From AM-00...
04/10/2025 12:06:12

– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its ...

Maxim Group Downgrades Galmed Pharmaceutic...
04/04/2025 13:20:41

Maxim Group analyst Naz Rahman downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold.

Galmed Pharmaceuticals Files Annual Report...
04/02/2025 20:15:16

TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ('Galmed' or the 'Company...

Galmed Pharmaceuticals Announces The Grant...
03/20/2025 12:57:54

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical compa...

Galmed Pharmaceuticals Shares Resumed Trade
03/17/2025 13:43:46